Get started
Author

David H. Cordover

Observed names: D. Cordover, David Cordover
OpenAlex ID: A5066972897
The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents
2015 · Jude Canon, Tao Osgood, et al. · Molecular Cancer Therapeutics · 150
Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody
2010 · Angela Coxon, James Bready, et al. · Molecular Cancer Therapeutics · 148
Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer
2020 · Sanghoon Lee, Li Zhao, et al. · Cell Reports · 118
Local Delivery of OncoVEXmGM-CSF Generates Systemic Antitumor Immune Responses Enhanced by Cytotoxic T-Lymphocyte–Associated Protein Blockade
2017 · Achim K. Moesta, Keegan Cooke, et al. · Clinical Cancer Research · 108
Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats
2015 · Michael S. Ominsky, Danielle L. Brown, et al. · Bone · 93
PDF
Antidiabetic effects of 11β‐HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis
2009 · D. J. Lloyd, J. Helmering, et al. · Diabetes Obesity and Metabolism · 39
Supplemental Figure 2 from The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents
2023 · Jude Canon, Tao Osgood, et al.
Supplemental Figure 1 from The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents
2023 · Jude Canon, Tao Osgood, et al.
Supplemental Figure 3 from The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents
2023 · Jude Canon, Tao Osgood, et al.
Supplemental Figure 2 from The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents
2023 · Jude Canon, Tao Osgood, et al.
Supplemental Figure 3 from The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents
2023 · Jude Canon, Tao Osgood, et al.
Supplemental Figure 1 from The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents
2023 · Jude Canon, Tao Osgood, et al.
Data from The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents
2023 · Jude Canon, Tao Osgood, et al.
Data from The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents
2023 · Jude Canon, Tao Osgood, et al.
Supplementary Methods, Figure Legends, and References from Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody
2023 · Angela Coxon, James Bready, et al.
PDF
Data from Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody
2023 · Angela Coxon, James Bready, et al.
Supplementary Figure 4 from Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody
2023 · Angela Coxon, James Bready, et al.
Supplementary Figure 1 from Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody
2023 · Angela Coxon, James Bready, et al.
PDF
Supplementary Figure 2 from Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody
2023 · Angela Coxon, James Bready, et al.
Supplementary Figure 3 from Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody
2023 · Angela Coxon, James Bready, et al.
Data from Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody
2023 · Angela Coxon, James Bready, et al.
Supplementary Figure 4 from Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody
2023 · Angela Coxon, James Bready, et al.
PDF
Supplementary Figure 1 from Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody
2023 · Angela Coxon, James Bready, et al.
Supplementary Figure 3 from Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody
2023 · Angela Coxon, James Bready, et al.
PDF
Supplementary Methods, Figure Legends, and References from Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody
2023 · Angela Coxon, James Bready, et al.
Works count: 31
Citation count: 656
H-index: 6
I10-index: 6
Year
Topic
Type